Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.46 |
| ▸ | NPC1 | O15118 | 6/20 | 0.46 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.46 |
| ▸ | TDO2 | P48775 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11479791 | 0.69 | LIMK1 (0.52) | RAB9ANPC1LIMK1TDO2MEN1 | |
| SCHEMBL4177850 | 0.66 | TDO2 (0.53) | RAB9ANPC1TDO2MEN1KMT2A | |
| SCHEMBL19009938 | 0.66 | TDO2 (0.45) | RAB9ANPC1LIMK1TDO2MEN1 | |
| SCHEMBL911402 | 0.65 | MAPT (0.56) | ALDH1A1MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL21857026 | 0.64 | MAP2K3 (0.58) | RAB9ANPC1LIMK1TDO2MEN1 | |
| SCHEMBL13040787 | 0.64 | NLRP3 (0.57) | RAB9ANPC1LIMK1TDO2MEN1 | |
| SCHEMBL23972163 | 0.63 | NPC1 (0.47) | RAB9ANPC1LIMK1MEN1KMT2A | |
| SCHEMBL19805090 | 0.63 | NPC1 (0.61) | RAB9ANPC1LIMK1MEN1KMT2A | |
| SCHEMBL19335781 | 0.63 | MEN1 (0.52) | RAB9ALIMK1TDO2MEN1KMT2A | |
| SCHEMBL14884091 | 0.63 | RAB9A (0.52) | RAB9ANPC1LIMK1TDO2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2582709-B1 | AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | SANOFI SA (FR) | 2018-01-24 | — | — | EP | disclosed |
| EP-2582709-B1 | AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | SANOFI SA (FR) | 2018-01-24 | — | — | EP | disclosed |
| US-8933024-B2 | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases | SANOFI (FR) | 2015-01-13 | — | — | US | disclosed |
| US-8933024-B2 | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases | SANOFI (FR) | 2015-01-13 | — | — | US | disclosed |
| US-8933024-B2 | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases | SANOFI (FR) | 2015-01-13 | — | — | US | disclosed |
| US-20130157941-A1 | AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | SANOFI (FR) | 2013-06-20 | — | — | US | disclosed |
| US-20130157941-A1 | AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | SANOFI (FR) | 2013-06-20 | — | — | US | disclosed |
| US-20130157941-A1 | AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | SANOFI (FR) | 2013-06-20 | — | — | US | disclosed |
| EP-2582709-A1 | AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | SANOFI (FR) | 2013-04-24 | — | — | EP | disclosed |
| WO-2011157827-A1 | AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | SANOFI (FR) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011157827-A1 | AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | SANOFI (FR) | 2011-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130157941-A1 | AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | PNLIP, LPL, CEL | RAB9A 2796/4885NPC1 1556/4885LIMK1 2121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.